Mesoblast
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Mesoblast sits in the top decile of US sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count).
Mesoblast: 25 sponsored US clinical trials, 1 recruiting.
Mesoblast sponsors 25 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 24 completed. 11 of these trials are in Phase 3-4 (later-stage) and 14 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Degenerative Disc Disease, with 2 trials.
Top-decile sponsor footprint
Mesoblast ranks in the top decile of sponsors by registered trial count (#626 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
24 of 24 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (100.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
25 total, page 1 of 1
Efficacy and Safety of Rexlemestrocel-L Combined With HA* in Participants With Moderate to Severe Chronic Low Back Pain
NCT06325566
Safety Follow-up of Treatment With Remestemcel-L in Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute GVHD
NCT02652130
A Prospective Study of Remestemcel-L, Ex-vivo Cultured Adult Human Mesenchymal Stromal Cells, for the Treatment of Pediatric Participants Who Have Failed to Respond to Steroid Treatment for Acute Graft-Versus-Host Disease (aGVHD)
NCT02336230
Placebo-controlled Study to Evaluate Rexlemestrocel-L Alone or Combined With Hyaluronic Acid in Participants With Chronic Low Back Pain
NCT02412735
Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure
NCT02032004
P3 Study of Umbilical Cord Blood Cells Expanded With MPCs for Transplantation in Patients With Hematologic Malignancies
NCT01854567
A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNFα Inhibitor
NCT01851070
Safety Study of Mesenchymal Precursor Cells in Type 2 Diabetes
NCT01576328
Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects With Lumbar Back Pain
NCT01290367
Evaluation of PROCHYMAL® for Treatment-refractory Moderate-to-severe Crohn's Disease
NCT01233960
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Undergoing Multi-Level Anterior Cervical Discectomy
NCT01097486
Safety and Preliminary Efficacy Study of NeoFuse in Subjects Requiring Lumbar Interbody Fusion
NCT00996073
Prochymal® (Human Adult Stem Cells) Intravenous Infusion Following Acute Myocardial Infarction (AMI)
NCT00877903
A Phase II Dose-escalation Study to Assess the Feasibility and Safety of Transendocardial Delivery of Three Different Doses of Allogeneic Mesenchymal Precursor Cells (MPCs)in Subjects With Heart Failure
NCT00721045
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
NCT00690066
PROCHYMAL™ (Human Adult Stem Cells) for the Treatment of Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
NCT00683722
Efficacy and Safety of Prochymal® Infusion in Combination With Corticosteroids for the Treatment of Newly Diagnosed Acute Graft Versus Host Disease (GVHD)
NCT00562497
Study of 3 Doses of NeoFuse Combined With MasterGraft Granules in Subjects Requiring Posterolateral Lumbar Fusion (PLF)
NCT00549913
Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-resistant Moderate-to-severe Crohn's Disease
NCT00482092
Extended Evaluation of PROCHYMAL® Adult Human Stem Cells for Treatment-Resistant Moderate-to-Severe Crohn's Disease
NCT00543374
Efficacy and Safety of Adult Human Mesenchymal Stem Cells to Treat Steroid Refractory Acute Graft Versus Host Disease (GVHD)
NCT00366145
Prochymal™ Adult Human Mesenchymal Stem Cells for Treatment of Moderate-to-severe Crohn's Disease
NCT00294112
Safety and Efficacy of Prochymal for the Salvage of Treatment-Refractory Acute GVHD Participants
NCT00284986
Safety and Efficacy Study of Adult Human Mesenchymal Stem Cells to Treat Acute Graft Versus Host Disease (GVHD)
NCT00136903
Safety Study of Adult Mesenchymal Stem Cells (MSC) to Treat Acute Myocardial Infarction
NCT00114452
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 11 |
| Phase 3 | 11 |
Therapeutic Areas
What is open in the Mesoblast pipeline
1 recruiting of 25 indexed (4% open); 24 completed (96%).
Phase mix: 11 late (III/IV) vs 14 early (I/II) (balanced across stages).
Top condition: Degenerative Disc Disease (2 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Mesoblast: open-pipeline peers nationwide
Peers matched on 25 registered trials and 4% open enrollment, not the therapeutic-area sidebar.
Mesoblast sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 25 trials (± recruiting share)
- Arcus Biosciences · 25 trials · 12% recruiting
- Arcutis Biotherapeutics · 25 trials · 8% recruiting
- Ardelyx · 25 trials · 12% recruiting
- Drexel University College of Medicine · 25 trials · 0% recruiting
Sponsors near 4% open enrollment (± trial volume)
- Fisher and Paykel Healthcare · 4% recruiting · 25 trials
- ResMed · 4% recruiting · 25 trials
- Sangamo Therapeutics · 4% recruiting · 25 trials
- MedtronicNeuro · 4% recruiting · 51 trials
Related
What to do with this Mesoblast page
25 registered trials is a research-attention snapshot, not an endorsement of Mesoblast or any single study.
- 1 of Mesoblast's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Degenerative Disc Disease is the condition Mesoblast studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Degenerative Disc Disease trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mesoblast pipeline card: 25 registered trials from official public datasets.Report a data error.